Thais Soares Cianciarullo Minett

Thais Soares Cianciarullo Minett

Auto-generated profile, based on publicly available information

Thais Soares Cianciarullo Minett

Department of Radiology, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2007 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
TMThaís Soares Cianciarullo Minett
Thaís Soares Cianciarullo Minett
RSRosimeire Vieira Da Silva
Rosimeire Vieira Da Silva
KOKarin Zazo Ortiz
Karin Zazo Ortiz
PBPaulo Henrique Ferreira Bertolucci
Paulo Henrique Ferreira Bertolucci

25 April 2018 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
TMThais Minett
Thais Minett
LSLi Su
Li Su
EMElijah Mak
Elijah Mak
GWGuy Williams
Guy Williams
MFMichael Firbank
Michael Firbank
JOJohn T. O’bRien
John T. O’bRien
To investigate whether white matter microstructural changes can be used as a predictor of worsening of motor features or cognitive decline in patients with Parkinson’s disease and verify whether white matter microstructural longitudinal changes differ between patients with Parkinson’s disease with normal cognition and those with mild cognitive impairment.

1 August 2005 in The American Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
TMT. S.C. Minett
T. S.C. Minett

9 December 2023 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Open access
PDF file
TBThomas C Booth
Thomas C Booth
ABAhmed Bassiouny
Ahmed Bassiouny
JLJeremy Oliver Lynch
Jeremy Oliver Lynch
HSHemant Sonwalkar
Hemant Sonwalkar
ABAaron Bleakley
Aaron Bleakley
ASAnand Sastry
Anand Sastry
Background The Pipeline Vantage Embolization Device (PEDV) is the fourth-generation pipeline flow diverter for intracranial aneurysm treatment. There are no outcome studies for the second PEDV version. We aimed to evaluate safety and efficacy outcomes. Primary and secondary objectives were to determine outcomes for unruptured and ruptured cohorts, respectively. Methods In this multicenter retrospective and prospective study, we analyzed outcome data from eight centers using core laboratory assessments. We determined 30-day and ≥3-month mortality and morbidity rates, and 6- and 18-month radiographic aneurysm occlusion rates for procedures performed during the period July 2021–March 2023. Results We included 121 consecutive patients with 131 aneurysms. The adequate occlusion rate for the unruptured cohort at short-term and medium-term follow up, and also for the ruptured cohort at short-term follow up, was >90%. Two aneurysms (1.5%) underwent retreatment. When mortality attributed to a palliative case in the unruptured cohort, or subarachnoid hemorrhage in the ruptured cohort, was excluded then the overall major adverse event rate in respective cohorts was 7.5% and 23.5%, with 0% mortality rates for each. When all event causes were included on an intention-to-treat basis, the major adverse event rates in respective cohorts were 8.3% and 40.9%, with 0.9% and 22.7% mortality rates. Conclusions For unruptured aneurysm treatment, the second PEDV version appears to have a superior efficacy and similar safety profile to previous-generation PEDs. These are acceptable outcomes in this pragmatic and non-industry-sponsored study. Analysis of ruptured aneurysm outcomes is limited by cohort size. Further prospective studies, particularly for ruptured aneurysms, are needed.

20 September 2013 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
JPJoelma Karin Sagica Fernandes Paschoal
Joelma Karin Sagica Fernandes Paschoal
JLJaime Lin
Jaime Lin
RPRicardo Silva Pinho
Ricardo Silva Pinho
SASolange Andreoni
Solange Andreoni
TMThais Soares Cianciarullo Minett
Thais Soares Cianciarullo Minett
MMMarcelo Rodrigues Masruha
Marcelo Rodrigues Masruha

9 June 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
KOKarin Zazo Ortiz
Karin Zazo Ortiz
Juliana Onofre de LiraJuliana Onofre de Lira
Juliana Onofre de Lira
TMThais Soares Ciariancullo Minett
Thais Soares Ciariancullo Minett
PBPaulo Henrique Ferreira Bertolucci
Paulo Henrique Ferreira Bertolucci
Background: During the moderate stage of dementia due to Alzheimer’s disease (AD), language disorder is more evident and it impacts on communication. An overview of language impairment could be helpful to find compensatory communication strategies for these patients. Objective: To identify all language impairments among patients with moderate-stage of AD. Methods: 20 patients diagnosed with probable AD based on the criteria of the NINCDS-ARDRA, with a MMSE score of 13-23 points and CDR=2, who were undergoing treatment for AD with therapeutic doses of acetyl cholinesterase inhibitors, were assessed using the Boston Diagnostic Aphasia Examination (BDAE), a test that provides a broad assessment of language. The results were compared with the performance of a normal population. Results: The patients assessed in this study presented normal scores for oral and written word recognition, repetition, mechanics of writing, primer-level dictation and spelling to dictation but also had impairment at most levels of linguistic processing, in oral and written comprehension and production. In general, as expected, the tasks relying on access to the mental lexicon were most significantly affected. However, they performed well in the naming task, in which semantic cues were presented. Moreover, the patients assessed in this study had better performance in written comprehension tasks than in oral ones. Conclusion: The severity of the language impairments was not homogenous, with some linguistic abilities more impaired than others. The abilities that were found to be preserved can help to guide strategies for aiding in communication at this stage of AD.